CLRB Cellectar Biosciences Inc.

2.54
+0.06  (+2%)
Previous Close 2.48
Open 2.44
Price To Book 2.15
Market Cap 23,847,139
Shares 9,396,036
Volume 49,307
Short Ratio
Av. Daily Volume 125,464
Stock charts supplied by TradingView

NewsSee all news

  1. Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

    FLORHAM PARK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  2. Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer

    FLORHAM PARK, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  3. Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)

    FLORHAM PARK, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  4. Cellectar Biosciences to Present at Biotech Showcase 2020

    FLORHAM PARK, N.J., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  5. Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study

    30% overall response rate seen with an average progression free survival of 4.5 months and an acceptable and expected safety profile Additional data in patients receiving higher fractionated doses of CLR 131 anticipated

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data update February 19, 2020, CC 10:30 am EST.
CLR 131 - CLOVER-1
Various lymphoma
Phase 1 data update February 19, 2020, CC 10:30 am EST.
CLR 131
Multiple myeloma
Phase 1 trial to continue to higher dose - August 14, 2019.
CLR 131 (CLOVER-2)
Solid tumors

Latest News

  1. Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

    FLORHAM PARK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  2. Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer

    FLORHAM PARK, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  3. Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)

    FLORHAM PARK, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  4. Cellectar Biosciences to Present at Biotech Showcase 2020

    FLORHAM PARK, N.J., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  5. Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study

    30% overall response rate seen with an average progression free survival of 4.5 months and an acceptable and expected safety profile Additional data in patients receiving higher fractionated doses of CLR 131 anticipated

  6. Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium

    FLORHAM PARK, N.J., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  7. Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference

    50% overall response rate in cohort of patients receiving fractionated 37.5 mCi/m2 dose of CLR 131 31.3% overall response rate in multiple myeloma patients over all dose levels, including single bolus and fractionated

  8. Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference

    FLORHAM PARK, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  9. Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

    FLORHAM PARK, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  10. Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

    FLORHAM PARK, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  11. Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology

    Data demonstrate phospholipid ether (PLE) molecules ability to target wide range of tumors FLORHAM PARK, N.J., Oct. 15, 2019 (GLOBE NEWSWIRE) --  Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage

  12. Cellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology

    FLORHAM PARK, N.J., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  13. Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress

    FLORHAM PARK, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  14. Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma

    FLORHAM PARK, N.J., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  15. Cellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    FLORHAM PARK, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  16. Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

    Data presented at the 17th International Myeloma Workshop Patients in Cohort 6 achieved a meaningful clinical benefit with a 50% overall response rate and 100% disease control FLORHAM PARK, N.J., Sept. 16, 2019

  17. Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019

    FLORHAM PARK, N.J., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  18. Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

    FLORHAM PARK, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the